| Dr David B Tarullo, MD | |
|
1233 E 2nd St, Casper, WY 82601-2926 | |
| (307) 577-2222 | |
| Not Available |
| Full Name | Dr David B Tarullo |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 1233 E 2nd St, Casper, Wyoming |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295034874 | NPI | - | NPPES |
| 137545800 | Medicaid | WY | |
| 455399 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 9672A (Wyoming) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wyoming Medical Center | Casper, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Medical Physicians Pc | 4385771757 | 14 |
News Archive
Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients.
Researchers know what causes endometriosis, but how the cysts that are characteristic of the disease maintain themselves and produce severe pain in some women has remained a mystery.
Various news outlets report on the enrollment totals through December - and some demographic data - for Alabama, Wisconsin, Connecticut, Georgia, California, Illinois and others.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
Infiniti Research, a world-renowned market intelligence solutions provider, has announced the completion of their latest article on the interesting healthcare quality improvement tips to improve patient care.
› Verified 1 days ago
| Entity Name | Memorial Hospital Of Converse County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356496491 PECOS PAC ID: 2264340843 Enrollment ID: O20031203000672 |
News Archive
Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients.
Researchers know what causes endometriosis, but how the cysts that are characteristic of the disease maintain themselves and produce severe pain in some women has remained a mystery.
Various news outlets report on the enrollment totals through December - and some demographic data - for Alabama, Wisconsin, Connecticut, Georgia, California, Illinois and others.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
Infiniti Research, a world-renowned market intelligence solutions provider, has announced the completion of their latest article on the interesting healthcare quality improvement tips to improve patient care.
› Verified 1 days ago
| Entity Name | Emergency Medical Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720310709 PECOS PAC ID: 4385771757 Enrollment ID: O20100416000684 |
News Archive
Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients.
Researchers know what causes endometriosis, but how the cysts that are characteristic of the disease maintain themselves and produce severe pain in some women has remained a mystery.
Various news outlets report on the enrollment totals through December - and some demographic data - for Alabama, Wisconsin, Connecticut, Georgia, California, Illinois and others.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
Infiniti Research, a world-renowned market intelligence solutions provider, has announced the completion of their latest article on the interesting healthcare quality improvement tips to improve patient care.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David B Tarullo, MD Po Box 50770, Casper, WY 82605-0770 Ph: (307) 333-6910 | Dr David B Tarullo, MD 1233 E 2nd St, Casper, WY 82601-2926 Ph: (307) 577-2222 |
News Archive
Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients.
Researchers know what causes endometriosis, but how the cysts that are characteristic of the disease maintain themselves and produce severe pain in some women has remained a mystery.
Various news outlets report on the enrollment totals through December - and some demographic data - for Alabama, Wisconsin, Connecticut, Georgia, California, Illinois and others.
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
Infiniti Research, a world-renowned market intelligence solutions provider, has announced the completion of their latest article on the interesting healthcare quality improvement tips to improve patient care.
› Verified 1 days ago
Dr. Jerry Robert Realing, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1233 E 2nd St, Casper, WY 82601 Phone: 307-333-6910 Fax: 307-333-6912 | |
Dr. Ryan Scott Benson, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1233 E 2nd St, Casper, WY 82601 Phone: 307-333-6910 Fax: 307-333-6912 | |
Makenzie Volker Bartsch, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2510 E 15th St Ste 12, Casper, WY 82609 Phone: 307-333-6910 Fax: 307-333-6912 | |
Dr. Travis Paul Washut, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1233 E 2nd St, Casper, WY 82601 Phone: 307-333-6910 Fax: 307-333-6912 | |
Joel M Pull, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4450 E 24th St, Casper, WY 82609 Phone: 307-254-2472 | |
Michael R Bruno, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1233 E 2nd St, Casper, WY 82601 Phone: 307-333-6910 Fax: 307-333-6912 |